The assays allow the clinicians to manage the treatment of patients infected with Human Immunodeficiency Virus (HIV-1) or Hepatitis C (HCV).
Roche Diagnostics COO Roland Diggelmann said: "The cobas 6800/8800 Systems represent the next generation of molecular diagnostic instruments that offer unparalleled performance, unmatched flexibility and absolute automation.
"By virtue of their design and clinical utility, the cobas HIV-1 and cobas HCV tests set new industry standards for viral load assays, delivering on Roche’s commitment to provide new diagnostic tools to advance the medical community’s understanding about viral disease and improve the ability to treat patients."
Roche noted that the assays launched will be followed in the coming months by the cobas CMV and cobas HBV assays, which will complete the primary portfolio of viral load monitoring assays for the cobas 6800/8800 Systems.
The assays for new molecular diagnostic platforms are available in all the countries accepting CE-mark, and are not currently available in the US, according to Roche.
Cobas 6800 and 8800 Systems are fully automated solutions developed for blood donor screening, viral load monitoring, women’s health and microbiology testing.
Image: The administration and R&D buildings, Roche Diagnostics Ltd, Rotkreuz. Photo: courtesy of F. Hoffmann-La Roche Ltd.
